Drug development in children and adolescents occasionally is hindered by a hesitance to expose young patients to experimental and untested therapies, such as the application of biologic agents for pediatric patients with inflammatory bowel disease (IBD). This collection of articles from JPGN represent seminal work on the application, safety, and efficacy of the 2 leading anti-TNF agents, infliximab and adalimumab, to assist readers in considering treatment options and further advances in the care of pediatric patients with chronic IBD.
|Publisher||Wolters Kluwer Health Adis (ESP)|
|Number of pages||379|
|State||Published - 24 Apr 2014|